Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses the use of systemic therapies vs biologics and why adherence is so important when treating patients with atopic dermatitis (AD).
Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, outlines his process for selecting which patients are best suited for which atopic dermatitis (AD) treatment.
Transcript
How do you decide who is eligible for systemic therapy for AD?
Candidates for systemic therapy vs candidates for topical therapy is usually a decision that’s really important for us when we're seeing an AD patient and when we're seeing a psoriasis patient, and I use a number of different factors.
The first obvious one is the extent and severity of the disease. So, if someone has extensive AD, or very severe disease, it's obvious that they are candidates for systemic therapy. And then the other end of the spectrum, when it's obvious the AD is fairly limited, fairly mild, that patient’s going to be definitely a candidate for topical therapy.
I think in between are the hard cases. You have patients who are episodically bad, that is maybe a couple times a year. And historically, those patients have been treated with courses of prednisone, which I really don't like at all. And I'm more of a fan of using systemic therapy to prevent those episodic outbreaks in that type of patient.
I think another patient that emerges as a candidate for systemic therapy is one who has used topical therapy for many years and is frustrated by the level of control and the amount of disease that they have remaining. And instead of just keeping on doing the serial topical therapy and re-upping the 1-lb jar of triamcinolone, I think that's the type of patient who's also a candidate for systemic therapy; those who have been on topical therapy for a very long time and are frustrated by it and want something different.
Should patient adherence to other AD therapies play a role in deciding if biologics are the right choice?
Topical therapy, let's start with that. It's hard to do it every day like we want patients to do it, so I don't blame them. Instead of admonishing our patients for not using their topical therapy appropriately, you should recognize that they're not going to be doing that, and that may lead you towards more systemic therapy. We have oral options that are 1 pill once a day. That can be tough to do. And then you have biologics that tend to be a shot every 2 weeks, every 4 weeks, or so.
I think in a lot of ways, biologics can enhance or improve adherence, because it's only 2 times a month or once a month where they have to remember to do something.
We think of shots as inconvenient, but it actually is pretty convenient only to do something once or twice a month compared to doing something on a daily basis, so I do think biologics can help improve adherence with patients.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More